Your browser doesn't support javascript.
loading
Dexamethasone decreases migraine recurrence observed after treatment with a triptan combined with a nonsteroidal anti-inflammatory drug
Krymchantowski, Abouch V; Barbosa, Jackeline Soraya.
Afiliação
  • Krymchantowski, Abouch V; Headache Center of Rio. BR
  • Barbosa, Jackeline Soraya; Headache Center of Rio. BR
Arq. neuropsiquiatr ; 59(3B): 708-711, Sept. 2001. tab
Artigo em Inglês | LILACS | ID: lil-295835
Biblioteca responsável: BR1.1
RESUMO
BACKGROUND AND

OBJECTIVES:

Triptans are effective drugs for the acute treatment of migraine. However, 30-40 percent of the patients commonly present recurrence before 24 hours therefore requiring another dose. Nonsteroidal anti-inflammatory drugs (NSAID) such as tolfenamic acid and naproxen sodium combined with sumatriptan have demonstrated efficacy in reducing recurrence observed with the single use of this drug. Steroids also have been suggested to treat refractory migraine and status migranosus. The aim of this study was to evaluate whether patients presenting frequent recurrence with the combination triptan plus NSAID, would decrease it with the association of dexamethasone.

METHOD:

Twenty three patients, 17 women and 6 men with migraine according to IHS criteria were prospectively studied. All patients presented frequent recurrence ( > or = 60 percent, mean recurrence rate 74,8 percent) with the single use of sumatritpan 100mg or zolmitriptan 2,5mg or rizatriptan 10mg in at least 5 consecutive attacks, and didn't present a reduction of the recurrence rate superior than 20 percent with the combination of tolfenamic acid 200mg or rofecoxib 25mg in at least 5 other consecutive attacks (mean recurrence rate 60 percent). The patients had to treat 6 consecutive moderate or severe migraine attacks with their usual combination plus 4mg of dexamathasone with a maximum of twice a week, and fill out a diary reporting headache parameters.

RESULTS:

Twenty patients, 16 women and 4 men completed the study. Of those who completed the study, 11 took rizatriptan plus rofecoxib, 4 rizatriptan plus tolfenamic acid, 3 zolmitriptan plus rofecoxib, 1 zolmitriptan plus tolfenamic acid and 1 patient took sumatriptan plus tolfenamic acid, having the 20 patients taken as a third medication, a single tablet of 4mg of dexamethasone. All patients took oral formulations and none presented vomiting after that. Among all 20 patients, one female and one male patient presented recurrence in 3 out of the 6 attacks (50 percent) while the remaining 18 patients revealed recurrence in 1 or 2 treated attacks (mean 23,4 percent) (p<0,001).

CONCLUSION:

We concluded that the judicious use of oral dexamethasone might be useful for a limited population of migraine patients still presenting recurrence with the combination of a triptan and a NSAID. Case-control studies and studies with a randomized double-blind design are necessary to confirm these observations
Assuntos
Texto completo: Disponível Coleções: Bases de dados internacionais Base de dados: LILACS Assunto principal: Dexametasona / Anti-Inflamatórios não Esteroides / Agonistas do Receptor de Serotonina / Sumatriptana / Anti-Inflamatórios / Transtornos de Enxaqueca Tipo de estudo: Ensaio clínico controlado / Estudo observacional / Fatores de risco Limite: Adulto / Feminino / Humanos / Masculino Idioma: Inglês Revista: Arq. neuropsiquiatr Assunto da revista: Neurologia / Psiquiatria Ano de publicação: 2001 Tipo de documento: Artigo País de afiliação: Brasil Instituição/País de afiliação: Headache Center of Rio/BR
Texto completo: Disponível Coleções: Bases de dados internacionais Base de dados: LILACS Assunto principal: Dexametasona / Anti-Inflamatórios não Esteroides / Agonistas do Receptor de Serotonina / Sumatriptana / Anti-Inflamatórios / Transtornos de Enxaqueca Tipo de estudo: Ensaio clínico controlado / Estudo observacional / Fatores de risco Limite: Adulto / Feminino / Humanos / Masculino Idioma: Inglês Revista: Arq. neuropsiquiatr Assunto da revista: Neurologia / Psiquiatria Ano de publicação: 2001 Tipo de documento: Artigo País de afiliação: Brasil Instituição/País de afiliação: Headache Center of Rio/BR
...